The R-Opra plant (part of the R-Pharm group) in the Alabushevo Technopolis Moscow Special Economic Zone has launched aseptic production of injectable drugs for the treatment of severe and chronic diseases. This was announced by the head of the Moscow Department of Investment and Industrial Policy, Anatoly Garbuzov.
The first product was an eribulin-based drug used in the treatment of breast cancer and liposarcoma.
“The R-Opra plant has begun producing drugs that require special, stringent aseptic conditions. They are used for severe and chronic diseases, such as cancer pathologies,” Garbuzov noted (quote from mos.ru). In the near future, the site plans to start production of two more cancer drugs.
“Sterile production expands the possibilities for localizing drugs that are critical for clinical practice. This helps reduce dependence on external supplies in a number of therapeutic areas,” added R-Opra Production Director Elena Lyutina.
The plant was opened in 2023 as part of an offset contract with the Moscow government. The enterprise manufactures drugs vital to the healthcare system for the treatment of socially significant diseases, including cancer, autoimmune conditions, and asthma.
At the end of last year, the company announced plans to launch new cancer drugs on the market. According to R-Pharm’s Director of Science and Research, Olga Filon, 15 molecules are in the final stages of development — their registration is planned within the next two years. The portfolio is based on generic chemical and biological drugs, including biosimilars of monoclonal antibodies.
